MX2010002115A - 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. - Google Patents

2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.

Info

Publication number
MX2010002115A
MX2010002115A MX2010002115A MX2010002115A MX2010002115A MX 2010002115 A MX2010002115 A MX 2010002115A MX 2010002115 A MX2010002115 A MX 2010002115A MX 2010002115 A MX2010002115 A MX 2010002115A MX 2010002115 A MX2010002115 A MX 2010002115A
Authority
MX
Mexico
Prior art keywords
ttk
treatment
anilinopurin
mps1
inhibitors
Prior art date
Application number
MX2010002115A
Other languages
English (en)
Inventor
David Michael Andrews
Clifford David Jones
Richard Andrew Ward
Irain Simpson
Original Assignee
Aztrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aztrazeneca Ab filed Critical Aztrazeneca Ab
Publication of MX2010002115A publication Critical patent/MX2010002115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos químicos de la fórmula (I), o una sal farmacéuticamente aceptable de los mismos, que poseen actividad inhibitoria contra la cinasa de punto de control de huso, tirosina treonina cinasa (TTK)/huso monopolar 1 (Mps1), y por consiguiente son útiles por su efecto anticáncer en un animal de sangre caliente tal como uh humano. La invención también se refiere a procesos para la fabricación de los compuestos químicos, composiciones farmacéuticas que los contienen, y a su uso en la fabricación de un medicamento para el tratamiento de condiciones mediadas por TTK/Mps1, para uso solo o en combinación con otros agentes anti-proliferativos.
MX2010002115A 2007-08-23 2008-08-20 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. MX2010002115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95750807P 2007-08-23 2007-08-23
PCT/GB2008/050724 WO2009024824A1 (en) 2007-08-23 2008-08-20 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
MX2010002115A true MX2010002115A (es) 2010-06-01

Family

ID=39951669

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002115A MX2010002115A (es) 2007-08-23 2008-08-20 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.

Country Status (19)

Country Link
US (1) US20110118238A1 (es)
EP (1) EP2212326A1 (es)
JP (1) JP2010536841A (es)
KR (1) KR20100057650A (es)
CN (1) CN103298814A (es)
AU (1) AU2008290330A1 (es)
BR (1) BRPI0815709A2 (es)
CA (1) CA2696200A1 (es)
CO (1) CO6260060A2 (es)
CR (1) CR11295A (es)
DO (1) DOP2010000064A (es)
EA (1) EA201000341A1 (es)
EC (1) ECSP10010034A (es)
MX (1) MX2010002115A (es)
NI (1) NI201000032A (es)
NZ (1) NZ584138A (es)
SV (1) SV2010003491A (es)
WO (1) WO2009024824A1 (es)
ZA (1) ZA201001193B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
FR2955109B1 (fr) 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
UY33452A (es) 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
EP2651945A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
ES2544609T3 (es) * 2010-12-17 2015-09-02 Bayer Intellectual Property Gmbh Imidazopirazinas 2-sustituidas para uso como inhibidores de Mps-1 y TTK en el tratamiento de trastornos hiper-proliferativos
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるｍｐｓ−１およびｔｋｋ阻害剤としての使用のための、イミダゾピラジン類
EP2651947B1 (en) * 2010-12-17 2014-12-10 Bayer Intellectual Property GmbH 6-thio-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
EP2651950A1 (en) * 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2012080234A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
DK2699575T3 (da) 2011-04-21 2015-06-22 Bayer Ip Gmbh Triazolopyridiner
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
ES2605946T3 (es) 2012-03-14 2017-03-17 Bayer Intellectual Property Gmbh Imidazopiridazinas sustituidas
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
EP3004092B1 (en) * 2013-06-07 2017-03-22 Bayer Pharma Aktiengesellschaft Substituted triazolopyridines
RS56034B1 (sr) 2013-06-11 2017-09-29 Bayer Pharma AG Derivati prolekova supstituisanih triazolopiridina
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CA2981844A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
UA123032C2 (uk) 2016-12-20 2021-02-03 Астразенека Аб Амінотриазолопіридинові сполуки та їхнє застосування у лікуванні раку
US11052091B2 (en) 2016-12-21 2021-07-06 Ono Pharmaceutical Co., Ltd. BRK inhibitory compound
TWI820146B (zh) * 2018-06-15 2023-11-01 瑞典商阿斯特捷利康公司 嘌呤酮化合物及其在治療癌症中之用途
WO2021209055A1 (zh) * 2020-04-17 2021-10-21 成都百裕制药股份有限公司 咪唑啉酮衍生物及其在医药上的应用
KR102409595B1 (ko) * 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CZ309356B6 (cs) * 2020-09-15 2022-09-28 Ústav experimentální botaniky AV ČR, v. v. i Substituované purinové sloučeniny jako inhibitory proteinkináz, jejich použití jako léčiva a farmaceutické přípravky obsahující tyto deriváty
WO2022135360A1 (zh) * 2020-12-21 2022-06-30 江苏恒瑞医药股份有限公司 嘌呤酮衍生物、其制备方法及其在医药上的应用
WO2022199547A1 (zh) * 2021-03-22 2022-09-29 成都赜灵生物医药科技有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
WO2023025160A1 (zh) * 2021-08-23 2023-03-02 成都百裕制药股份有限公司 一种咪唑啉酮衍生物的制备工艺及其中间体
JP2024533674A (ja) * 2021-09-23 2024-09-12 チェンドゥ バイユー ファーマシューティカル カンパニー リミテッド イミダゾリノン誘導体の結晶形
TW202402282A (zh) * 2022-07-13 2024-01-16 大陸商成都百裕製藥股份有限公司 咪唑啉酮衍生物在製備用於聯合放療治療腫瘤的藥物中的應用
WO2024017220A1 (zh) * 2022-07-20 2024-01-25 成都百裕制药股份有限公司 咪唑啉酮衍生物联合多柔比星在治疗肿瘤中的应用
WO2024125304A1 (zh) * 2022-12-13 2024-06-20 成都百裕制药股份有限公司 一种咪唑啉酮类化合物药物制剂及其制备方法及用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006205851A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JO3235B1 (ar) * 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها

Also Published As

Publication number Publication date
NI201000032A (es) 2010-12-07
DOP2010000064A (es) 2010-03-31
EA201000341A1 (ru) 2010-10-29
BRPI0815709A2 (pt) 2017-06-13
KR20100057650A (ko) 2010-05-31
ZA201001193B (en) 2010-10-27
US20110118238A1 (en) 2011-05-19
CO6260060A2 (es) 2011-03-22
JP2010536841A (ja) 2010-12-02
ECSP10010034A (es) 2010-04-30
WO2009024824A1 (en) 2009-02-26
CA2696200A1 (en) 2009-02-26
CN103298814A (zh) 2013-09-11
CR11295A (es) 2010-05-28
NZ584138A (en) 2011-10-28
AU2008290330A1 (en) 2009-02-26
EP2212326A1 (en) 2010-08-04
SV2010003491A (es) 2010-07-06

Similar Documents

Publication Publication Date Title
MX2010002115A (es) 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos.
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
EA033343B1 (ru) Соединения, ингибирующие rip2-киназу, фармацевтическая композиция на их основе и их применение для лечения заболеваний, опосредуемых rip2-киназой
WO2012028332A8 (en) Pharmaceutically active compounds as axl inhibitors
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
GB201104267D0 (en) Pyrrolopyridineamino derivatives
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
BR112014028954A2 (pt) amidas de n-piridinila substituídas no anel como inibidores da quinase
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
MX2013008161A (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
BR112012031634A2 (pt) composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
WO2009057139A3 (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
TN2015000555A1 (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase

Legal Events

Date Code Title Description
FA Abandonment or withdrawal